ABSTRACT
Purpose Evidence suggests that older adults, racial/ethnic minorities, and those with comorbidities all face elevated risk for morbidity and mortality from COVID-19; but there are limited reports describing the potential for interactions between these factors.
Methods We sought to evaluate age-based heterogeneity in observed disparities in hospitalization, ICU admission, and mortality related to COVID-19 using CDC public use surveillance data on 3,662,325 COVID-19 cases reported from January 1 to August 30, 2020.
Results Racial/ethnic and comorbidity disparities in hospitalization were most pronounced during ages 20-29 and ages 10-19, with similar elevation seen for disparities in ICU risk.
Racial/ethnic disparities in mortality were most pronounced during ages 20-29 while risk from comorbidity peaks among ages 10-39.
Conclusions As COVID-19 continues to affect younger populations, special attention to the implications for the most vulnerable subgroups are clearly warranted.
Implications and Contribution Adolescents and young adults appear to have experienced the greatest inequities in COVID-19 outcomes by race/ethnicity and comorbidity. Careful monitoring of trends in this population is warranted as they re-enter school, work, and social settings while being the last group to receive priority for vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We wish to acknowledge the generous funding support for investigator time provided by the National Institute of Diabetes and Digestive and Kidney Diseases K01DK116932 (PI: Wisk).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As data were publicly-available, this study was exempt from IRB review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Source: We wish to acknowledge the generous funding support for investigator time provided by the National Institute of Diabetes and Digestive and Kidney Diseases K01DK116932 (PI: Wisk).
Conflict-of-Interest Disclosure: None
Abbreviations
- COVID-19
- Coronavirus disease 2019
- CDC
- Centers for Disease Control and Prevention
- RR
- Relative risk
- CI
- Confidence interval
- ICU
- Intensive care unit
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
2
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos